Johnson & Johnsonchalks up its recent oncology successes to increased R&D investment and a comprehensive, focused oncology strategy in particular disease areas – with hematological malignancies as a top target.
The company had a history in oncology with products like Doxil (doxorubicin) and Procrit (epoetin alfa) and the proteasome inhibitor...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?